4-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]benzenesulfonamide | 946861-26-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]benzenesulfonamide
• 英文别名: 4-chloro-N-[(1S)-3,3,3-trifluoro-1-hydroxymethyl-2-trifluoromethyl-propyl]-benzenesulfonamide；4-Chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoro-methyl)propyl]benzenesulfonamide；4-chloro-N-[(2S)-4,4,4-trifluoro-1-hydroxy-3-(trifluoromethyl)butan-2-yl]benzenesulfonamide
• CAS: 946861-26-3
• 化学式: C₁₁H₁₀ClF₆NO₃S
• 分子量: 385.715
• InChiKey: OWNAZRSXJRXLGP-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  4-chloro-N-(3,3,3-trifluoro-1-hydroxymethyl-2-trifluoromethyl-propyl)-benzenesulfonamide 以 ipa 、 正己烷 为溶剂， 生成 4-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]benzenesulfonamide
  参考文献：
  名称：

  Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors

  摘要：

  提供了Formula (I)的化合物，或其药用可接受的盐和/或水合物或前药，其中Formula (I)具有以下结构： 在此定义了R1-R7。这些化合物在治疗从阿尔茨海默病、淀粉样血管病、脑淀粉样血管病、全身性淀粉样病、荷兰型遗传性脑出血伴淀粉样病、包涵体肌炎、轻度认知障碍（MCI）和唐氏综合征等疾病的药物中对受试者有用。

  公开号：

  US20070249722A1

文献信息

• Selective n-sulfonylation of 2-amino flouro-and trifluoroalkyl substituted alcohols
  申请人：Chan Anita Wai-Yin

  公开号：US20070197800A1

  公开（公告）日：2007-08-23

  Processes for preparing sulfonamide trifluoroalkyl substituted alcohol compounds are provided. Desirably, the compounds are heterocyclic sulfonamide trifluoroalkyl substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl substituted alcohol compounds.

  提供了制备磺胺三氟烷基取代醇化合物的过程。理想情况下，这些化合物是杂环磺胺三氟烷基取代醇化合物或苯基磺胺三氟烷基取代醇化合物。
• COMPOSITIONS CONTAINING O-SULFATE AND O-PHOSPHATE CONTAINING ARYL SULFONAMIDE DERIVATIVES USEFUL AS beta-AMYLOID INHIBITORS
  申请人：LI David Zenan

  公开号：US20090181932A1

  公开（公告）日：2009-07-16

  A synthetic compound characterized by having the structure of formula I or II or a pharmaceutically acceptable salt and/or hydrate thereof is provided. Formula I and formula II are defined as follows. wherein R 1 is substituted aryl or substituted heteroaryl; R 2 and R 3 are independently selected from the group consisting of CF 3 , substituted phenyl, C 1 -C 4 alkyl, substituted C 1 -C 4 alkyl, (CF 3 ) n C 1 -C 4 alkyl, (CF 3 ) n (substituted C 1 -C 4 alkyl), provided that when R 2 or R 3 is CF 3 , the other is not an unsubstituted alkyl; R 4 and R 4′ are independently selected from the group consisting of M, C 1 -C 4 alkyl, phenyl, and benzyl, wherein M is a metal ion is selected from the group consisting of sodium, lithium, calcium, magnesium and potassium, or R 4 and R 4′ are taken together to form a cyclic structure. Methods of making such compounds and uses thereof are also provided.

  提供一种具有I或II式结构或其药学上可接受的盐和/或水合物的合成化合物。其中，公式I和公式II定义如下：其中R1为取代芳基或取代杂环芳基；R2和R3分别选自CF3、取代苯基、C1-C4烷基、取代C1-C4烷基、( )nC1-C4烷基、( )n(取代C1-C4烷基)的群，但当R2或R3为 时，另一个不是未取代的烷基；R4和R4′分别选自M、C1-C4烷基、苯基和苄基的群，其中M是选择自钠、锂、钙、镁和钾的金属离子，或R4和R4′结合形成环状结构。还提供制备这种化合物的方法和其用途。
• Methods for preparing sulfonamide substituted alcohols and intermediates thereof
  申请人：Chan Anita Wai-Yin

  公开号：US20070197830A1

  公开（公告）日：2007-08-23

  Processes for preparing amino alcohols or salts thereof and sulfonamide substituted alcohol compounds are provided. Desirably, the sulfonamide substituted alcohol compounds are heterocyclic sulfonamide trifluoroalkyl-substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl-substituted alcohol compounds.

  提供了制备氨基醇或其盐以及磺酰胺取代的醇化合物的工艺。理想情况下，磺酰胺取代的醇化合物是杂环磺酰胺三氟烷基取代的醇化合物或苯基磺酰胺三氟烷基取代的醇化合物。
• TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS
  申请人：Porte Alexander Michael

  公开号：US20090221711A1

  公开（公告）日：2009-09-03

  A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R 1 -R 7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

  提供了公式（I）的化合物，或其药学上可接受的盐和/或水合物或前药，其中公式（I）具有结构：其中R1-R7在此定义。这些化合物在治疗以下疾病的药物中有用，所述疾病选自阿尔茨海默病，淀粉样血管病，脑淀粉样血管病，全身性淀粉样变性，荷兰型遗传性脑出血伴有淀粉样沉积，包涵体肌病，轻度认知障碍（MCI）和唐氏综合症。
• Selective N-sulfonylation of 2-amino fluoro- and trifluoroalkyl substituted alcohols
  申请人：Wyeth LLC

  公开号：US07838550B2

  公开（公告）日：2010-11-23

  Processes for preparing sulfonamide trifluoroalkyl substituted alcohol compounds are provided. Desirably, the compounds are heterocyclic sulfonamide trifluoroalkyl substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl substituted alcohol compounds.

  提供了制备磺酰胺三氟烷基取代醇类化合物的过程。理想情况下，这些化合物是杂环磺酰胺三氟烷基取代醇类化合物或苯基磺酰胺三氟烷基取代醇类化合物。